Jagannadha Rao Kandula
About Jagannadha Rao Kandula
Jagannadha Rao Kandula is the Head of LCM & New Technology Commercialization, Cell Therapy Process Engineering, GMS&T at Bristol Myers Squibb, with extensive experience in biologics and cell therapy development.
Current Role at Bristol Myers Squibb
Jagannadha Rao Kandula currently holds the position of Head of LCM & New Technology Commercialization, Cell Therapy Process Engineering, GMS&T at Bristol Myers Squibb. In this role, he is responsible for managing product life cycle strategy changes and executing the commercialization of new technologies for CAR-T cell therapy products. His extensive experience also includes handling global regulatory submissions and overseeing commercial dossiers and inspections.
Professional Experience at Bristol Myers Squibb
Before his current position, Jagannadha Rao Kandula served in various impactful roles at Bristol Myers Squibb. From 2020 to 2021, he was the Head of LCM, GMS&T, Cell Therapy Development & Operations. Prior to this, he was the Director of Biologics External Manufacturing from 2019 to 2020. His earlier tenure at the company included roles as Manager/Process Engineer from 2004 to 2009 and as Process Engineer in 2004.
Previous Roles at Celgene
Jagannadha Rao Kandula worked extensively at Celgene, where he held the position of Director, Biologics DS Development & Clinical Manufacturing from 2013 to 2019. He was also the Associate Director, Biologics Operations from 2009 to 2013. During his tenure, he led process development and scale-up of live viral vaccines using anchor-dependent cells in suspension culture mode with microcarriers.
Academic Background
Jagannadha Rao Kandula earned his Ph.D. in Biochemical Engineering and Biotechnology from the Indian Institute of Technology, Madras, completing his studies between 1992 and 1997. He also held postdoctoral positions at several prestigious institutions, including the University of Western Ontario, New York University - Polytechnic School of Engineering, and the Korea Research Institute of Bioscience and Biotechnology.
Expertise in Biologics and Regulatory Submissions
Jagannadha Rao Kandula possesses in-depth knowledge of global regulatory submissions, including BLA, MAA, and CTD. He has expertise in filing commercial dossiers, handling IR responses, and overseeing Pre-Approval Inspections. Additionally, he has served as the CMC Leader for multiple biologics compound teams, managing CMC development through various clinical phases, including strategy development, scale-up, and technology transfer.